Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

October 27, 2014

Primary Completion Date

June 11, 2018

Study Completion Date

December 18, 2018

Conditions
Hematological NeoplasmsNon-Hodgkin's LymphomaHodgkin's LymphomaLymphomaMultiple MyelomaAcute Myeloid LeukemiaLeukemiaMyelodysplastic SyndromesNeoplasmsMelanomaBreast CancerMetastatic Breast CancerNon-Small Cell Lung CancerSmall Cell Lung CancerRenal Cell CarcinomaGlioblastoma MultiformeOsteosarcomaSarcomaThyroid CancerGenitourinary
Interventions
DRUG

CC-486

Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2

DRUG

Vidaza

75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles

Trial Locations (10)

29605

Greenville Hospital System, Greenville

44195

Cleveland Clinic Foundation, Cleveland

52242

University of Iowa, Iowa City

77030

The Methodist Hospital Research Institute l, Houston

85258

Scottsdale Healthcare Research Institute, Scottsdale

85259

Mayo Clinic - Arizona, Scottsdale

85724

University of Arizona Cancer Center, Tucson

48202-268

Henry Ford Health System, Detroit

08903

Cancer Institute of New Jersey, New Brunswick

37232-6307

Vanderbilt- Ingram Cancer Center, Nashville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT02223052 - Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | Biotech Hunter | Biotech Hunter